Qualips has revised its full-year consolidated earnings forecast for the fiscal year ending March 2027 upward, projecting sales of 540 million yen and net profit of 570 million yen. The adjustments are due to the reimbursement price decision for Rehart and related insurance claims, resulting in improved sales and profits.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4894","jir_company_name":"Qualips Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-07-28","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4894-20260728-01.pdf","jir_short_summary":"Qualips has revised its full-year consolidated earnings forecast for the fiscal year ending March 2027 upward, projecting sales of 540 million yen and net profit of 570 million yen. The adjustments are due to the reimbursement price decision for Rehart and related insurance claims, resulting in improved sales and profits.","jir_summary":"### Performance Overview\nQualips has revised its full-year consolidated earnings forecast for the fiscal year ending March 2027 upward, with projected sales of 540 million yen and net income attributable to owners of parent of \u25b369.01 million yen. The revisions reflect improved sales and profits driven by the reimbursement price decision for Rehart and subsidies received, with a reduction in operating loss.\n\n### Future Outlook and Impact\nThe reimbursement price decision for Rehart has clarified sales outlooks, with expected sales increases following the product's launch after September 2026. Subsidies received are also contributing to profit improvements, and these factors are anticipated to be significant in future business development.","jir_financial_highlights":"Sales: 540 million yen (Increase from previous forecast (A) of 0 million yen)\nNet income attributable to owners of parent: \u25b369.01 million yen (Improvement from previous forecast (A) of \u25b3168.33 million yen)\nOperating profit: \u25b31,030 million yen (Narrowing from previous forecast (A) of \u25b31,430 million yen)","jir_category":"","jir_hashtags":"#QualipsCorporation, #IRrelated, #JapanStocks","jir_key_figures":"Sales: 540 million yen\nNet income attributable to owners of parent: \u25b369.01 million yen\nOperating profit: \u25b31,030 million yen","jir_meta_title":"\u3010Qualips\u3011Upward Revision of Full-Year Earnings Forecast | July 2026","jir_meta_description":"Qualips has revised its full-year consolidated earnings forecast for the fiscal year ending March 2027 upward, projecting sales of 540 million yen and net profit of \u25b369.01 million yen. The reimbursement decision for Rehart contributed positively.","jir_og_title":"\u3010Qualips\u3011Earnings Forecast Revision | July 2026","jir_og_description":"Qualips has upwardly revised its earnings forecast for the fiscal year ending March 2027, with sales of 540 million yen and net profit of \u25b369.01 million yen. Details are available in IR materials.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":17194,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-89045","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n